

# **CureVac: Finale Analyse der zulassungsrelevanten Phase 2b/3-Studie HERALD**

Donnerstag, 1. Juli 2021

*Pressekonferenz*

The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.


This presentation of CureVac N.V. and/or its wholly owned subsidiaries CureVac AG, CureVac Real Estate GmbH, CureVac Inc., CureVac Swiss AG and CureVac Corporate Services GmbH (the “company”) contains statements that constitute “forward-looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections of the company regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the potential efficacy of the company’s vaccine and treatment candidates and the company’s strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” or “expect,” “may,” “will,” “would,” “could,” “potential,” “intend,” or “should,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company’s performance, and you should not place undue reliance on such statements.

Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and


collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in the company’s industry, the effects of the COVID-19 pandemic on the company’s business and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability to provide for patient safety, and fluctuations of operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this presentation are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

For further information, please reference the company’s reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at [www.sec.gov](http://www.sec.gov).

# Die HERALD-Studie: Geografisch vielfältig und variantenreich



# COVID-19-Realität: Besorgniserregende Varianten breiten sich in Europa und Lateinamerika aus



\*Stand 25. Juni 2021; Quelle: [www.nextstrain.org](http://www.nextstrain.org) / Südamerika- oder Europa-fokussierte Teilstichproben

# Wirksamkeitsprofil in der Altersgruppe 18 bis 60 zur Bekämpfung der Pandemie und der Variantenausbreitung



## IN DER ALTERSGRUPPE VON 18 BIS 60 JAHREN

**100 %**

(0 Impfstoffgruppe vs.  
6 Placebo-Gruppe)

**SCHUTZ VOR KRANKENHAUS-  
AUFENTHALT ODER TOD**

**77 %**

(9 Impfstoffgruppe vs.  
36 Placebo-Gruppe)

**SCHUTZ VOR MODERATER BIS  
SCHWERER ERKRANKUNG**

**53 %**

(71 Impfstoffgruppe vs.  
136 Placebo-Gruppe)

**GESAMTWIRKSAMKEIT DES  
IMPFSTOFFS CVNCOV**

PRIMÄRER  
WIRKSAMKEITSENDPUNKT

**48%**


IN ALLEN  
ALTERSGRUPPEN

**228**

bestätigte COVID-19-Fälle

# Die HERALD-Studie: Schlüsseldaten der finalen Analyse

## Ursprünglicher Stamm



**21%** Lambda (C.37)



## 15 COVID-19-STÄMME

~ 51%	Besorgniserregende Varianten
~ 35%	Varianten von besonderem Interesse
~ 11%	Weniger erforschte Varianten
~ 3%	Wildtyp-Stamm



- 1** Einzigartige zulassungsrelevante Studie mit 40.000 Probanden in zehn Ländern auf zwei Kontinenten in beispielloser Studiumgebung mit 15 aufgetretenen Virusstämmen
- 2** Gutes CVnCoV-Wirksamkeitsprofil in der Altersgruppe von 18 bis 60 Jahren mit signifikantem Schutz vor moderater bis schwerer Erkrankung und Hospitalisierung oder Tod über alle Varianten
- 3** Volles Engagement für die Fortsetzung der regulatorischen Zulassungsprozesse und laufender Dialog mit der Europäischen Arzneimittelagentur (EMA)
- 4** Weiterhin Aufbau der Produktionskapazitäten und erfolgreich laufendes COVID-19-Programm mit Partner GSK für COVID-19-Impfstoffe der zweiten Generation





**HERZLICHEN DANK FÜR  
IHRE AUFMERKSAMKEIT**

CureVac  
[www.curevac.com](http://www.curevac.com)